Q3 2020 13F Holders as of 30 Sep 2020
-
Type / Class
-
Debt / NOTE 3.250% 7/0
-
Market price (% of par)
-
80.48%
-
Total 13F principal
-
$469,032,500
-
Principal change
-
+$1,000
-
Total reported market value
-
$379,338,906
-
Number of holders
-
46
-
Value change
-
+$2,391,122
-
Number of buys
-
14
-
Number of sells
-
23
Institutional Holders of INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 as of Q3 2020
As of 30 Sep 2020,
INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 was held by
46 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$469,032,500
in principal (par value) of the bond.
The largest 10 bondholders included
WOLVERINE ASSET MANAGEMENT LLC, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), UBS ASSET MANAGEMENT AMERICAS INC, DeepCurrents Investment Group LLC, ADVENT CAPITAL MANAGEMENT /DE/, OAKTREE CAPITAL MANAGEMENT LP, HIGHBRIDGE CAPITAL MANAGEMENT LLC, Context Capital Management, LLC, Context Partners Fund, L.P., and MORGAN STANLEY.
This page lists
46
institutional bondholders reporting positions
for the Q3 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.